For the quarter ended June 2025, Boston Scientific (BSX) reported revenue of $5.06 billion, up 22.8% over the same period last year. EPS came in at $0.75, compared to $0.62 in the year-ago quarter.
The reported revenue represents a surprise of +3.48% over the Zacks Consensus Estimate of $4.89 billion. With the consensus EPS estimate being $0.72, the EPS surprise was +4.17%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Boston Scientific performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Geographic Revenue- Rest of the World: $1.84 billion versus $1.82 billion estimated by three analysts on average.
- Geographic Revenue- U.S.: $3.22 billion versus the three-analyst average estimate of $3.06 billion. The reported number represents a year-over-year change of +30.7%.
- Net Sales- Cardiovascular- Peripheral Interventions- International: $296 million compared to the $309.92 million average estimate based on two analysts. The reported number represents a change of +5.3% year over year.
- Net Sales- MedSurg- Neuromodulation- United States: $228 million compared to the $220.82 million average estimate based on two analysts. The reported number represents a change of +6.5% year over year.
- Net Sales- MedSurg- Worldwide: $1.72 billion versus $1.68 billion estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +15.7% change.
- Net Sales- Cardiovascular- Worldwide: $3.35 billion compared to the $3.21 billion average estimate based on six analysts. The reported number represents a change of +26.9% year over year.
- Net Sales- Cardiovascular- Cardiology- Worldwide: $2.65 billion versus the five-analyst average estimate of $2.52 billion. The reported number represents a year-over-year change of +29.3%.
- Net Sales- Cardiovascular- Peripheral Interventions- Worldwide: $698 million versus $689.56 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +18.3% change.
- Net Sales- MedSurg- Endoscopy- Worldwide: $737 million versus $715.15 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +9% change.
- Net Sales- MedSurg- Neuromodulation- Worldwide: $303 million versus the five-analyst average estimate of $292.59 million. The reported number represents a year-over-year change of +7.5%.
- Net Sales- MedSurg- Urology- Worldwide: $676 million compared to the $671.66 million average estimate based on five analysts. The reported number represents a change of +28.8% year over year.
- Net Sales- Cardiovascular- Cardiac Rhythm Management (CRM)- Worldwide: $590 million versus the four-analyst average estimate of $587.42 million. The reported number represents a year-over-year change of +2.4%.
View all Key Company Metrics for Boston Scientific here>>>
Shares of Boston Scientific have returned -0.9% over the past month versus the Zacks S&P 500 composite's +5.9% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Boston Scientific Corporation (BSX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
